摘要
目的:观察缬沙坦对肝硬化患者血流动力学指标及CGRP、HA、CG、PAI-1的影响.方法:肝硬化患者随机分为对照组和治疗组各18例,对照组给予常规治疗,治疗组在此基础上加用缬沙坦80mg/dpo,疗程1mo.治疗前后应用彩色多普勒超声仪检测门、脾静脉的内径与流速,同时采用放免法检测血CGRP、HA、CG的水平,酶联免疫法测定血PAI-1的水平.结果:缬沙坦可使门、脾静脉的内径减小,流速增快.缬沙坦亦可降低患者CGRP、HA、CG、PAI-1的水平(73.15±14.59ng/Lvs75.79±15.06ng/L,422.34±183.94μg/Lvs498.39±197.53μg/L,12.50±8.92mg/Lvs24.23±13.05mg/L,28.09±10.80μg/Lvs32.56±11.18μg/L,均P<0.05).结论:缬沙坦能够在一定程度上降低门静脉压力,同时具有一定的抗肝纤维化作用.
AIM： To observe the effects of valsartan on hemodynamic markers, CGRP, HA, CG and PAI-1 in patients with hepatic cirrhosis.METHODS： Thirty-six patients with hepatic cirrhosis were divided into control group and observation group. Eighteen patients in control group received routine treatment for 1 month and eighteen patients in observation group received valsartan 80 mg/d based on routine treatment for the same time. Diameter of portal or splenic vein and their mean velocity were measured before and after treatment by color Doppler. Blood levels of calcitonin gene related peptide （CGRP）, hyaluronic acid （HA）, cholyglycine （CG） were simultaneously assessed by radioimmunoassay. Plasminogen activator inhibitor-1 （PAI-1） was measured by ELISA.RESULTS： Valsartan reduced the diameter of portal or splenic vein and increased the mean velocity of portal or splenic vein.Valsartan also reduced the concentrations of CGRP, HA, CG and PAI-1 in blood （73.15 ± 14.59 vs 75.79 ± 15.06, 422.34 ± 183.94 vs 498.39 ± 197.53, 12.50 ± 8.92 vs 24.23 ± 13.05, 28.09 ± 10.80 vs 32.56 ± 11.18, all P 〈 0.05）.CONCLUSION： Valsartan can reduce portal hypertension and it may have the effect of anti-hepatic fibrosis.
出处
《世界华人消化杂志》
CAS
北大核心
2009年第11期1139-1142,共4页
World Chinese Journal of Digestology
关键词
缬沙坦
肝硬化
血流动力学
降钙素基因相关肽
肝纤维化
Valsartan
Hepatic cirrhosis
Hemodynamic
Calcitonin gene related peptide
Hepatic fibrosis
